Cargando…
Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium
The anti-diabetic and oral hypoglycaemic agent metformin, first used clinically in 1958, is today the first choice or ‘gold standard’ drug for the treatment of type 2 diabetes and polycystic ovary disease. Of particular importance for the treatment of diabetes, metformin affords protection against d...
Autores principales: | Kinaan, Mustafa, Ding, Hong, Triggle, Chris R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588255/ https://www.ncbi.nlm.nih.gov/pubmed/26021280 http://dx.doi.org/10.1159/000381643 |
Ejemplares similares
-
Endothelial Cell Dysfunction and the Vascular Complications Associated with Type 2 Diabetes: Assessing the Health of the Endothelium
por: Ding, Hong, et al.
Publicado: (2005) -
Metformin: An Old Drug with New Applications
por: Zhou, Joseph, et al.
Publicado: (2018) -
A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan
por: Mohammed, Ibrahim, et al.
Publicado: (2021) -
Repurposing metformin: an old drug with new tricks in its binding pockets
por: Pryor, Rosina, et al.
Publicado: (2015) -
Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer
por: Samuel, Samson Mathews, et al.
Publicado: (2019)